International Journal of Pharmaceutics-X

International Journal of Pharmaceutics: X is a gold open access companion journal to the International Journal of Pharmaceutics, published by Elsevier since 2019 with the same goals, scope and peer review process, covering the physical, chemical and biological properties of drugs, vaccines and biologics, with a 2025 Journal Impact Factor of 7.9 and a first-quartile rank of 25 among 356 pharmacology and pharmacy journals《国际药剂学杂志（X）》（International Journal of Pharmaceutics: X）是（International Journal of Pharmaceutics）的金色开放获取姊妹刊，（Elsevier）自 2019 年起出版，宗旨、范围与评审流程与主刊一致，覆盖药物、疫苗与生物制品的物理、化学和生物学性质，2025 年影响因子为 7.9，在 356 种药理与药学类期刊中列第 25 位，居第一四分位。

Scope

• The journal addresses the design, manufacturing and evaluation of dosage forms and drug delivery systems该刊关注剂型与药物递送系统的设计、制造与评价。
• It covers the physical, chemical and biological properties of drugs, vaccines and biologicals覆盖药物、疫苗与生物制品的物理、化学及生物学性质。
• Special attention is given to the characterization of drugs, excipients such as surfactants and polymers, and new materials尤其关注药物、表面活性剂与聚合物等辅料以及新材料的性质表征。
• Drug release mechanisms, mass transport phenomena and mathematical modelling of delivery systems are central topics药物释放机制、质量传递现象与递送系统的数学建模是核心议题。
• Nanomedicine, targeted delivery, and formulation strategies for poorly soluble or biological drugs are within scope纳米医学、靶向递送以及难溶性药物与生物药物的制剂策略均在范围内。
• Emerging manufacturing methods such as additive manufacturing, electrospinning and drug-device combination products are represented on the board's expertise list增材制造、静电纺丝与药械组合产品等新兴制造方法见于编委专长列表。
• Because it mirrors the parent journal, submissions judged more suited to the subscription title can be transferred between the two由于与主刊范围一致，被判断更适合订阅制主刊的稿件可在两刊之间转投。

History

• International Journal of Pharmaceutics: X was launched in 2019 as the gold open access companion of the International Journal of Pharmaceutics, which had been established in 1978该刊于 2019 年创刊，为（International Journal of Pharmaceutics）的金色开放获取姊妹刊，后者创刊于 1978 年。
• It was added to the Directory of Open Access Journals in September 2019, publishing under a CC BY-NC-ND licence with an article processing charge of 3,700 US dollars该刊 2019 年 9 月被（Directory of Open Access Journals）收录，以（CC BY-NC-ND）许可出版，文章处理费为 3,700 美元。
• The journal uses continuous publication, so articles receive a DOI and appear online as soon as they are accepted rather than waiting for an issue该刊采用连续出版，文章录用后即获得（DOI）并在线发布，无需等待成期。
• Its Journal Impact Factor rose from 5.679 in 2022 to 6.4 in 2024 and 7.9 in 2025, with a CiteScore of 8.9其影响因子由 2022 年的 5.679 升至 2024 年的 6.4 与 2025 年的 7.9，CiteScore 为 8.9。
• The journal reports an average of about seventeen weeks from submission to publication, reflecting the longer cycle typical of pharmaceutics papers with extensive experimental work该刊公布从投稿到发表平均约 17 周，反映药剂学论文实验工作量大、周期较长的特点。

Editors

• The Editor-in-Chief is Juergen Siepmann, professor of pharmaceutical technology at the University of Lille in France, who has led the journal since its launch现任主编为法国里尔大学药剂学教授 Juergen Siepmann，自创刊起主持该刊。
• Zhengrong Cui of the University of Texas at Austin handles submissions from North America得克萨斯大学奥斯汀分校的 Zhengrong Cui 负责北美地区稿件。
• Abdul Basit of UCL School of Pharmacy, Yongzhuo Huang of the Shanghai Institute of Materia Medica and Kiyohiko Sugano of Ritsumeikan University cover Japan and the Far East伦敦大学学院药学院的 Abdul Basit、中国科学院上海药物研究所的 Yongzhuo Huang 与立命馆大学的 Kiyohiko Sugano 负责日本及远东地区。
• Sara Nicoli of the University of Parma and Mingshi Yang of the University of Copenhagen serve as editors, while Juan M. Irache and Leena Peltonen handle reviews帕尔马大学的 Sara Nicoli 与哥本哈根大学的 Mingshi Yang 担任编辑，Juan M. Irache 与 Leena Peltonen 负责综述类稿件。
• The board lists 116 editors and members from 26 countries, including 21 in the United States, 18 in the United Kingdom and 12 in Italy, and the journal operates blind peer review编委会列出 116 位编辑与编委，来自 26 个国家，其中美国 21 人、英国 18 人、意大利 12 人，刊物实行盲审。